Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | PGR | P06401 | 2/20 | 0.37 |
| ▸ | ACACB | O00763 | 2/20 | 0.34 |
| ▸ | ACACA | Q13085 | 2/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.32 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5233706 | 0.91 | KCNH2 (0.38) | KCNH2PGRS1PR1 | |
| SCHEMBL5228368 | 0.89 | KCNH2 (0.36) | KCNH2PGRACACBS1PR1 | |
| SCHEMBL1347465 | 0.88 | HDAC6 (0.36) | KCNH2PGRS1PR1 | |
| Lersivirine SCHEMBL508446 | 0.83 | KCNH2 (0.49) | KCNH2PGR | |
| SCHEMBL508393 | 0.81 | KCNH2 (0.44) | KCNH2PGR | |
| SCHEMBL2717137 | 0.80 | KCNH2 (0.53) | KCNH2PGR | |
| SCHEMBL10251075 | 0.79 | KCNH2 (0.36) | KCNH2PGRS1PR1 | |
| Lersivirine SCHEMBL509058 | 0.79 | KCNH2 (0.45) | KCNH2PGR | |
| SCHEMBL2716684 | 0.79 | KCNH2 (0.54) | KCNH2PGR | |
| SCHEMBL2717095 | 0.79 | KCNH2 (0.42) | KCNH2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377556-B1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LTD (GB) | 2007-04-04 | — | — | EP | claimed |
| EP-1762567-A1 | Pyrazole derivatives for treating HIV | Pfizer Limited (GB) | 2007-03-14 | — | — | EP | claimed |
| EP-1377556-A1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | Pfizer Limited (GB) | 2004-01-07 | — | — | EP | claimed |
| US-20030100554-A1 | Pyrazole derivatives | JONES LYN HOWARD (GB) | 2003-05-29 | — | — | US | claimed |
| WO-2002085860-A1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LIMITED (GB) | 2002-10-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100554-A1 | Pyrazole derivatives | REV1, SARS1, CYP2F1 | KCNH2 3503/4885PGR 1045/4885ACACB 3304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.